Merck, known as MSD outside of the United States and Canada, and Acceleron Pharma Inc., a publicly traded biopharmaceutical company, announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Acceleron for $180 per share in cash for an approximate total equity value of $11.5 billion. Read more.